KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies.

Amanda J Sheets, Jeremy Dennison, Jason M Pogue, Keith S Kaye, Caroline Perry, Helen Millns, Jazmín Díaz-Regañón, Salim Janmohamed

Clin Infect Dis 82(4) e684-e692

PMID41495938
PMCIDPMC13131927
DOI10.1093/cid/ciaf722
发表日期2026-01-07
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:非 KM 图;Figure 3.:图注未提示 KM 曲线;Figure 4.:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Uncomplicated urinary tract infections (uUTIs) can cause distressing symptoms seriously impacting daily activities. Early symptom relief during treatment, though fundamental to patients, is often overlooked in clinical trials. Gepotidacin, a new antibacterial agent, was noninferior to the first-line treatment nitrofurantoin in two randomized controlled trials (EAGLE-2 [NCT04020341] and EAGLE-3 [NCT04187144]). The current analysis utilized pooled data from these two trials to evaluate symptom responses during and after treatment in participants with uUTI. METHODS: Participants were aged ≥12 years with at least two uUTI symptoms, urinary nitrite and/or pyuria, and no complicating factors. Participants were randomized 1:1 to oral gepotidacin (1500 mg) or nitrofurantoin (100 mg), both taken twice daily for 5 days. At baseline (Day 1), on-therapy (OT; Days 2-4), and test-of-cure (TOC; Days 10-13) visits, urinary symptoms were assessed (0-3; none-severe) from which a total score (0-12) was derived. RESULTS: Overall, 3136 participants were randomized (1572 gepotidacin, 1564 nitrofurantoin). Mean (median) baseline symptom scores for gepotidacin and nitrofurantoin arms were 7.1 (7.0) and 7.2 (7.0), respectively; at OT, this decreased to 3.6 (3.0) for both arms. At the OT visit, >80% of participants had clinical improvement/resolution. Among those with baseline symptoms affecting everyday activities (moderate or severe), 53.2% (728/1369) assigned gepotidacin and 53.6% (738/1377) assigned nitrofurantoin reported at OT that symptoms no longer affected everyday activities (mild or absent); at TOC, these percentages were 93.8% (1232/1313) and 93.3% (1254/1344), respectively. CONCLUSIONS: Gepotidacin and nitrofurantoin provide meaningful and similar early relief from uUTI symptoms.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Symptom scoring in EAGLE-2 and EAGLE-3.
非 KM Figure
Figure 2.Total clinical symptom score by visit (pooled intent-to-treat (ITT) population).
非 KM Figure
Figure 3.Individual clinical symptom scores by visit (pooled intent-to-treat (ITT) population).
非 KM Figure
Figure 4.Participants with symptoms no longer interfering with daily activities (mild/absent) at OT and TOC visits by baseline symptom severity (post-hoc analysis; pooled ITT population). Abbreviations: ITT, intent-to-treat; OT, on-therapy; TOC, test-of-cure.
非 KM Figure